KLK4
Basics
Aliases:
This biomarker is also known as:- PRSS17,
- Enamel matrix serine proteinase 1,
- Kallikrein-like protein 1,
- Prostase,
- EMSP1,
- Human kallikrein 4,
- Serine protease 17,
- PSTS,
- hK4,
- KLK-L1,
- Kallikrein-4,
Description…
The glandular kallikreins are a distinct group of serine proteases with molecular masses of 25,000 to 40,000. Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. This gene is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. Several human kallikrein genes have been isolated. hK4 is expressed in the prostate.
Attributes
| QA State: | Accepted |
|---|---|
| Type: | Protein |
| Short Name: |
Organs
The following organs have data associated with this biomarker…
Prostate
Attributes
| Phase: | One |
|---|---|
| QA State: | Accepted |
Overview
Kallikreins (KLKs) are highly conserved serine proteases that play key roles in a variety of physiological and pathological processes. KLK4 is regulated by androgens and is highly specific to prostate for expression. hK4 is intracellularly localized. KLK4 is predominantly expressed in the basal cells of the normal prostate gland and overexpressed in prostate cancer. hK4 has a unique structure and function compared with other members of the KLK family and may have a role in the biology and characterization of prostate cancer.
Performance Comment
hK2, hK4 and hK11 do not distinguish cases from controls in these populations.
Supporting Study Data
The following studies/protocols provide evidence supporting KLK4 indications for the Prostate…
Prostate Rapid Pre-Validation Set
Determine which markers move to validation using the prospectie prostate reference set samples.
View more about this studyBiomarker Characteristics Summary
No statistics found.
Decision Rule
No clinically useful decision rule found.
Additional Study-Specific Protocols
Study-Specific Publications
No study-specific publications defined.
Study-Specific Resources
No study-specific resources defined.
Prostate Rapid Reference Set Applicant: Diamandis - Mt Sinai (2006)
No abstract available.
View more about this studyBiomarker Characteristics Summary
| Notes | Sensitivity | Specificity | Prevalence | NPV | PPV | Specific Assay Type |
|---|---|---|---|---|---|---|
| Measured among 123 samples (60 controls and 63 cases). Among the cases, 33 had low Gleason grade (<7) and 30 had high Gleason grade (>=7). When comparing cases with Gleason grade >=7 (n=30) to the pool of controls and cases with Gleason grade <7 (n=93), the AUC was 0.55 (0.45, 0.64). No specific cutoff was preselected for this analysis. | 0.0 | 0.0 | 0.0 | |||
| Measured among 123 samples (60 controls and 63 cases). Among the cases, 33 had low Gleason grade (<7) and 30 had high Gleason grade (>=7). When comparing all cases (low and high Gleason grade) to controls, the AUC was 0.52 (0.44, 0.60). No specific cutoff was preselected for this analysis. | 0.0 | 0.0 | 0.0 |
Decision Rule
No clinically useful decision rule found.
Additional Study-Specific Protocols
Study-Specific Publications
No study-specific publications defined.
Study-Specific Resources
No study-specific resources defined.
Organ-Specific Protocols
No organ-specific protocols defined.
Organ-Specific Publications
No organ-specific publications defined.
Organ-Specific Resources
No organ-specific resources defined.
Studies
No associated studies or protocols found.
